biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
NovaPharmaNews editorial coverage mentioning Nanjing Legend Biotech — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
News & analysis
NovaPharmaNews articles mentioning Nanjing Legend Biotech — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Nanjing Legend Biotech — regulatory, clinical, and market analysis.
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.
Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis
Legend Biotech's stock experienced a significant surge following the release of initial in vivo CAR-T cell therapy data. This development signals a potential shift in the CAR-T landscape, with implications for manufacturing, accessibility, and competitive dynamics.